{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T22:48:22Z","timestamp":1792795702795,"version":"4.5.0"},"reference-count":16,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2023,5,23]],"date-time":"2023-05-23T00:00:00Z","timestamp":1684800000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,5,23]],"date-time":"2023-05-23T00:00:00Z","timestamp":1684800000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cerebellum"],"DOI":"10.1007\/s12311-023-01568-8","type":"journal-article","created":{"date-parts":[[2023,5,23]],"date-time":"2023-05-23T03:02:07Z","timestamp":1684810927000},"page":"775-777","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":34,"title":["A Milestone in the Treatment of Ataxias: Approval of Omaveloxolone for Friedreich Ataxia"],"prefix":"10.1007","volume":"23","author":[{"given":"S. H.","family":"Subramony","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D. L.","family":"Lynch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,5,23]]},"reference":[{"key":"1568_CR1","doi-asserted-by":"publisher","first-page":"1423","DOI":"10.1126\/science.271.5254.1423","volume":"271","author":"V Campuzano","year":"1996","unstructured":"Campuzano V, Montermini L, Molt\u00f2 MD, Pianese L, Coss\u00e9e M, Cavalcanti F, Monros E, Rodius F, Duclos F, Monticelli A, et al. Friedreich\u2019s ataxia: autosomal recessive disease caused by an intronic GAA triplet repeat expansion. Science. 1996;271:1423\u20137.","journal-title":"Science"},{"key":"1568_CR2","doi-asserted-by":"publisher","first-page":"1709","DOI":"10.1126\/science.276.5319.1709","volume":"276","author":"M Babcock","year":"1997","unstructured":"Babcock M, de Silva D, Oaks R, Davis-Kaplan S, Jiralerspong S, Montermini L, Pandolfo M, JKaplan J. Regulation of mitochondrial iron accumulation by Yfh1p, a putative homolog of frataxin. Science. 1997;276:1709\u201312.","journal-title":"Science"},{"key":"1568_CR3","doi-asserted-by":"publisher","first-page":"104606","DOI":"10.1016\/j.nbd.2019.104606","volume":"132","author":"MB Delatycki","year":"2019","unstructured":"Delatycki MB, Bidichandani SI. Friedreich ataxia - pathogenesis and implications for therapies. Neurobiol Dis. 2019;132:104606.","journal-title":"Neurobiol Dis"},{"key":"1568_CR4","doi-asserted-by":"publisher","first-page":"e1499","DOI":"10.1212\/WNL.0000000000200913","volume":"99","author":"C Rummey","year":"2022","unstructured":"Rummey C, Corben LA, Delatycki M, Wilmot G, Subramony SH, Corti M, Bushara K, Duquette A, Gomez C, Hoyle JC, et al. Natural history of Friedreich\u2019s ataxia: heterogeneity of neurological progression and consequences for clinical trial design. Neurology. 2022;99:e1499\u2013510.","journal-title":"Neurology"},{"key":"1568_CR5","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1016\/S1474-4422(21)00027-2","volume":"20","author":"K Reetz","year":"2021","unstructured":"Reetz K, Dogan I, Hilgers R-D, Giunti P, Parkinson MH, Mariotti C, Nanetti L, Durr A, Ewenczyk C, Boesch S, et al. Progression characteristics of the European Friedreich\u2019s Ataxia Consortium for Translational Studies (EFACTS): a 4-year cohort study. Lancet Neurol. 2021;20:362\u201372.","journal-title":"Lancet Neurol"},{"key":"1568_CR6","doi-asserted-by":"publisher","first-page":"878","DOI":"10.1016\/S1474-4422(07)70220-X","volume":"6","author":"NA Di Prospero","year":"2007","unstructured":"Di Prospero NA, Baker A, Jeffries N, Fischbeck KH. Neurological effects of high-dose idebenone in patients with Friedreich\u2019s ataxia: a randomised, placebo-controlled trial. Lancet Neurol. 2007;6:878\u201386.","journal-title":"Lancet Neurol"},{"issue":"Suppl 1","key":"1568_CR7","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1111\/jnc.12322","volume":"126","author":"MH Parkinson","year":"2013","unstructured":"Parkinson MH, Schulz JB, Giunti P. Co-enzyme Q10 and idebenone use in Friedreich\u2019s ataxia. J Neurochem. 2013;126(Suppl 1):125\u201341.","journal-title":"J Neurochem"},{"key":"1568_CR8","doi-asserted-by":"publisher","first-page":"502","DOI":"10.1002\/jimd.12285","volume":"44","author":"MY Qureshi","year":"2021","unstructured":"Qureshi MY, Patterson MC, Clark V, Johnson JN, Moutvic MA, Driscoll SW, Kemppainen JL, Huston J III, Anderson JR, Badley AD, et al. Safety and efficacy of (+)-epicatechin in subjects with Friedreich\u2019s ataxia: a phase II, open-label, prospective study. J Inherit Metab Dis. 2021;44:502\u201314.","journal-title":"J Inherit Metab Dis"},{"key":"1568_CR9","doi-asserted-by":"publisher","first-page":"1615","DOI":"10.1007\/s00415-022-11501-4","volume":"270","author":"DR Lynch","year":"2023","unstructured":"Lynch DR, Mathews KD, Perlman S, Zesiewicz T, Subramony S, Omidvar O, Vogel AP, Krtolica A, Litterman N, van der Ploeg L, et al. Double blind trial of a deuterated form of linoleic acid (RT001) in Friedreich ataxia. J Neurol. 2023;270:1615\u201323.","journal-title":"J Neurol"},{"key":"1568_CR10","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1002\/ana.24248","volume":"76","author":"M Pandolfo","year":"2014","unstructured":"Pandolfo M, Arpa J, Delatycki MB, Sang KHLQ, Mariotti C, Munnich A, Sanz-Gallego I, Tai G, Tarnopolsky MA, Taroni F, et al. Deferiprone in Friedreich ataxia: a 6-month randomized controlled trial. Ann Neurol. 2014;76:509\u201321.","journal-title":"Ann Neurol"},{"key":"1568_CR11","doi-asserted-by":"publisher","first-page":"e4253","DOI":"10.1371\/journal.pone.0004253","volume":"4","author":"V Paupe","year":"2009","unstructured":"Paupe V, Dassa EP, Goncalves S, et al. Impaired nuclear Nrf2 translocation undermines the oxidative stress response in Friedreich ataxia. PLoS One. 2009;4:e4253.","journal-title":"PLoS One"},{"key":"1568_CR12","doi-asserted-by":"publisher","first-page":"2858","DOI":"10.1016\/j.ajpath.2017.08.021","volume":"187","author":"A Anzovino","year":"2017","unstructured":"Anzovino A, Chiang S, Brown BE, et al. Molecular alterations in a mouse cardiac model of Friedreich ataxia: an impaired Nrf2 response mediated via upregulation of Keap1 and activation of the Gsk3beta axis. Am J Pathol. 2017;187:2858\u201375.","journal-title":"Am J Pathol"},{"key":"1568_CR13","doi-asserted-by":"publisher","unstructured":"Abeti R, Baccaro A, Esteras N, Giunti P. Novel Nrf2-inducer prevents mitochondrial defects and oxidative stress in Friedreich\u2019s ataxia models. Front Cell Neurosci. 2018:12. https:\/\/doi.org\/10.3389\/fncel.2018.00188.","DOI":"10.3389\/fncel.2018.00188"},{"key":"1568_CR14","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1002\/acn3.660","volume":"6","author":"DR Lynch","year":"2019","unstructured":"Lynch DR, Farmer J, Hauser L, et al. Safety, pharmacodynamics, and potential benefit of omaveloxolone in Friedreich ataxia. Ann Clin Transl Neurol. 2019;6:15\u201326.","journal-title":"Ann Clin Transl Neurol"},{"key":"1568_CR15","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1002\/ana.25934","volume":"89","author":"DR Lynch","year":"2021","unstructured":"Lynch DR, Chin MP, Delatycki MB, Subramony SH, Corti M, Hoyle JC, Boesch S, Nachbauer W, Mariotti C, Mathews KD, et al. Safety and efficacy of omaveloxolone in Friedreich ataxia (MOXIe study). Ann Neurol. 2021;89:212\u201325.","journal-title":"Ann Neurol"},{"key":"1568_CR16","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1002\/mds.29286","volume":"38","author":"DR Lynch","year":"2023","unstructured":"Lynch DR, Chin MP, Boesch S, Delatycki MB, Giunti P, Goldsberry A, Hoyle JC, Mariotti C, Mathews KD, Nachbauer W, et al. Efficacy of omaveloxolone in Friedreich\u2019s ataxia: delayed-start analysis of the MOXIe extension. Mov Disord. 2023;38:313\u201332.","journal-title":"Mov Disord"}],"container-title":["The Cerebellum"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12311-023-01568-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12311-023-01568-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12311-023-01568-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,19]],"date-time":"2024-03-19T05:19:07Z","timestamp":1710825547000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12311-023-01568-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5,23]]},"references-count":16,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2024,4]]}},"alternative-id":["1568"],"URL":"https:\/\/doi.org\/10.1007\/s12311-023-01568-8","relation":{},"ISSN":["1473-4230"],"issn-type":[{"value":"1473-4230","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,5,23]]},"assertion":[{"value":"9 May 2023","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 May 2023","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This paper is an invited editorial comment and does not report any original human or animal research. No ethical committee approval was needed for this work.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}},{"value":"Both the authors of this work were investigators in the pharmaceutical trials being commented on. They received research support from Reata Pharmaceuticals to conduct the trials and also participated in advisory board meetings for the company. DL did not receive compensation for his advisory board participation. There are no non-financial interests to report.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interests"}}]}}